{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:13:16Z","timestamp":1793679196078,"version":"4.5.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030902","name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030902","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\u03b2-Synuclein is an emerging synaptic blood biomarker for Alzheimer\u00b4s disease (AD) and correlates with cognitive impairment, brain atrophy and amyloid\/tau pathology. Longitudinal data from individual patients are missing so far but are important to evaluate how changes of \u03b2-synuclein might be used in early diagnosis, prediction, disease progression and treatment monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this observational study, we investigated serum \u03b2-synuclein by immunoprecipitation-mass spectrometry (IP-MS) in 463 participants from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) including clinically diagnosed cognitively unimpaired, mild cognitive impairment (MCI) and AD dementia subjects with\u2009\u2265\u20091 follow-up samples for 235 individuals and clinical follow-up for up to 19\u00a0years. CSF AD biomarker levels were available for 194 participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Participants (40.0% female,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009185) had a mean (\u00b1\u2009SD) age of 76.2\u2009\u00b1\u20096.7\u00a0years. The cross-sectional group comparison yielded higher \u03b2-synuclein levels in MCI and AD dementia compared with CU and in AD dementia vs MCI patients. Mean follow-up time of longitudinal serum samples was 2.3\u2009\u00b1\u20091.2\u00a0years. The longitudinal data indicate that \u03b2-synuclein levels are dynamic during all stages of the AD continuum (CU, MCI, dementia) with substantial inter-individual variation. \u03b2-Synuclein predicted MCI-to-dementia conversion and future cognitive decline and it performed better in discrimination of AD dementia patients than CSF neurogranin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our longitudinal data support the use of serum \u03b2-synuclein levels for prediction of future cognitive decline and MCI-to-dementia conversion but needing confirmation. Further studies with biologically and clinically defined participants must verify the trajectories of \u03b2-synuclein during the AD continuum.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-01973-1","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:17:27Z","timestamp":1770815847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Longitudinal changes of blood \u03b2-synuclein in cognitively unimpaired, mild cognitive impairment and sporadic Alzheimer\u00b4s disease"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-7023","authenticated-orcid":false,"given":"Patrick","family":"Oeckl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-8506","authenticated-orcid":false,"given":"Samir","family":"Abu-Rumeileh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Weise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4273-4267","authenticated-orcid":false,"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"1973_CR1","doi-asserted-by":"crossref","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S, Von Arnim CAF, Diehl-Schmid J, Froelich L, et al. Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer\u2019s Disease. J Proteome Res. 2020;19:1310\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32101007. Cited 2020 Mar 27.","DOI":"10.1021\/acs.jproteome.9b00824"},{"key":"1973_CR2","doi-asserted-by":"crossref","unstructured":"Oeckl P, Anderl\u2010Straub S, Danek A, Diehl\u2010Schmid J, Fassbender K, Fliessbach K, et al. Relationship of serum beta\u2010synuclein with blood biomarkers and brain atrophy. Alzheimer\u2019s Dement. 2023;19:1358\u201371. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36129098\/. Cited 2022 Oct 12.","DOI":"10.1002\/alz.12790"},{"key":"1973_CR3","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.1002\/alz.13046","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Bluma M, Bucci M, Halbgebauer S, Chiotis K, Sandebring-Matton A, et al. Blood \u03b2-synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimers Dement. 2023;19:4896\u2013907.","journal-title":"Alzheimers Dement"},{"key":"1973_CR4","doi-asserted-by":"crossref","unstructured":"Oeckl P, Janelidze S, Halbgebauer S, Stomrud E, Palmqvist S, Otto M, et al. Higher plasma \u03b2-synuclein indicates early synaptic degeneration in Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2023;19:5095\u2013102. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/alz.13103. Cited 2023 May 3.","DOI":"10.1002\/alz.13103"},{"key":"1973_CR5","doi-asserted-by":"crossref","unstructured":"Oeckl P, Wagemann O, Halbgebauer S, Anderl-Straub S, Nuebling G, Prix C, et al. Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181. Ann Neurol. 2022;92:6\u201310. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35340050\/. Cited 2022 Mar 29.","DOI":"10.1002\/ana.26360"},{"key":"1973_CR6","doi-asserted-by":"crossref","unstructured":"Oeckl P, Mayer B, Bateman RJ, Day GS, Fox NC, Huey ED, et al. Early increase of the synaptic blood marker \u03b2\u2010synuclein in asymptomatic autosomal dominant Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2025;21(4):e70146. Available from: https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.70146","DOI":"10.1002\/alz.70146"},{"key":"1973_CR7","doi-asserted-by":"crossref","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388(1):9\u201321. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36449413\/. Cited 2023 Jan 13.","DOI":"10.1056\/NEJMoa2212948"},{"key":"1973_CR8","doi-asserted-by":"crossref","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13(1):80. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33865446\/. Cited 2024 Oct 17.","DOI":"10.1186\/s13195-021-00813-8"},{"issue":"6","key":"1973_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2024.0991","volume":"81","author":"O Wagemann","year":"2024","unstructured":"Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, et al. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. JAMA Neurol. 2024;81(6):582\u201393. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38683602\/. Cited 2024 Apr 30.","journal-title":"JAMA Neurol"},{"key":"1973_CR10","doi-asserted-by":"crossref","unstructured":"Barba L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, Paolini Paoletti F, Gaetani L, et al. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease. Neurology. 2023;101:E50\u201362. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37188538\/. Cited 2023 Nov 9.","DOI":"10.1212\/WNL.0000000000207371"},{"issue":"12","key":"1973_CR11","first-page":"1144","volume":"96","author":"L Barba","year":"2025","unstructured":"Barba L, Bellomo G, Alcolea D, Wojdala AL, Gaetani L, Fortea J, et al. Serum level changes of the synaptic marker beta-synuclein in Alzheimer\u2019s disease continuum and other dementias. J Neurol Neurosurg Psychiatry. 2025;96(12):1144\u201353. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40571405\/. Cited 2025 Sep 30.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-01973-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-01973-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-01973-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:06:21Z","timestamp":1781633181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-01973-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1973"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-01973-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants gave written informed consent and all procedures were approved by the local Institutional Review Boards (IRB) of the participating sites in accordance with the Declaration of Helsinki. For or up-to-date information and information regarding subject recruitment, inclusion and exclusion criteria and procedures for serum sample collection see\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PO received research support from the ALS Association\/ALS Finding A Cure (24-SGP-691, 23-PPG-674\u20132)), Charcot Foundation (D.7090), DZNE Innovation-to-Application (I2A_call9_Oeckl), EU Horizon Europe (SYNAPSING), consulting fees from LifeArc and Fundamental Pharma and travel support from Biogen. SAR received research support from the Medical Faculty of Martin-Luther-University Halle-Wittenberg (Clinician Scientist Programm No. CS22\/06). MO received research support from German Federal Ministry of Education and Research (FTLDc 01GI1007A), the EU Joint Programme-Neurodegenerative Diseases networks Genfi-Prox (01ED2008A), the EU (MOODMARKER 01EW2008), the German Research Foundation\/DFG (SFB1279), the foundation of the state Baden-W\u00fcrttemberg (D.3830), Boehringer Ingelheim Ulm University BioCenter (D.5009), EU Horizon Europe (SYNAPSING), and the Thierry Latran Foundation. MO and PO are co-inventors of a patent application for using \u03b2-synuclein measurement in blood (EP4014048A1, US2022283184A1). The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}